Bergan T
Institute of Medical Microbiology, Kaptein W. Wilhelmsen of Frues, University of Oslo, Rikshospitalet, Oslo 0027, Norway.
Int J Antimicrob Agents. 2001 Sep;18(3):279-82. doi: 10.1016/s0924-8579(01)00382-x.
The consumption of antibacterials has remained relatively stable in Scandinavia and is low compared with most other countries. Measured as "Defined Daily Doses" (DDD), the highest consumption is found in Iceland and Finland, and the lowest in Denmark and Norway. The consumption in Iceland, Finland and Sweden is about twice that in Norway. The distribution of different classes of antimicrobials shows striking differences. Phenoxymethyl and benzylpenicillin make up about 55% of the DDDs in Sweden and 40% of the DDDs in Denmark and Norway, whereas the narrow-spectrum penicillins represent 20% of the DDDs in Iceland. Fluoroquinolones are little used except in Sweden where they account for about 10% of DDDs. The use of cephalosporins ranges from 1% (in Denmark) to 15% (in Finland) and between 3 and 5% in the other countries. The policy that narrow-spectrum penicillins may be used when necessary but broad-spectrum compounds should be avoided has the positive effect that there is greater susceptibility in the Nordic countries to these antibiotics than elsewhere.
在斯堪的纳维亚半岛,抗菌药物的消费量一直相对稳定,与大多数其他国家相比处于较低水平。以“限定日剂量”(DDD)来衡量,冰岛和芬兰的消费量最高,丹麦和挪威最低。冰岛、芬兰和瑞典的消费量约为挪威的两倍。不同类别的抗菌药物分布存在显著差异。苯氧甲基青霉素和苄青霉素在瑞典的DDD中约占55%,在丹麦和挪威的DDD中占40%,而窄谱青霉素在冰岛的DDD中占20%。除了在瑞典氟喹诺酮类药物占DDD的约10%外,其他地方很少使用。头孢菌素类药物的使用比例从丹麦的1%到芬兰的15%不等,在其他国家介于3%至5%之间。必要时可使用窄谱青霉素但应避免使用广谱化合物的政策产生了积极效果,即北欧国家对这些抗生素的敏感性高于其他地方。